The Colorado Center for Gynecologic Oncology is excited to share our August Newsletter providing patients with new information, upcoming events and inspiring stories.
Vaccination against the human papillomavirus (HPV) is highly protective against precancerous cervical lesions in adolescents and young women compared with placebo, especially those who are negative for HPV at the time of vaccination, a systematic Cochrane review concludes.Details
Women with endometriosis are at an increased risk of developing ovarian cancer, but not cervical cancer or other cancers affecting the female reproductive organs, a nationwide Finnish study suggests.Details
FDA Approves First Biosimilar to Neulasta to Help Reduce the Risk of Infection During Cancer Treatment
The U.S. Food and Drug Administration today approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the chance of infection as suggested by febrile neutropenia (fever, often with other signs of infection, associated with an abnormally low number of infection-fighting white blood cells), in patients with non-myeloid (non-bone marrow) cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.Details